Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Carolina Rudah / iStock What is the Maximum Recommended Semaglutide Dose for Weight Loss? The maximum recommended semaglutide dose for weight loss is 2.4 milligrams (mg) per week. Your healthcare ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

Real-time index price for S&P Smallcap 600 (IQY), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans. © 2024 Fortune Media IP Limited. All Rights ...

BMO Capital Markets models FY24 total revenues of $28.4 billion for semaglutide (Ozempic/Wegovy) and $17.7 billion for tirzepatide (Mounjaro/Zepbound). The company's pipeline includes promising ...

The agency has authorized Novo Nordisk’s Wegovy—which shares the same active ingredient, semaglutide, as Ozempic—for weight loss and lowering the risk of cardiovascular events like heart ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A ... of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another ...